Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sampatrilat is an effecive and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase. Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,820.00 | |
50 mg | 8-10 weeks | $ 2,380.00 | |
100 mg | 8-10 weeks | $ 3,100.00 |
Description | Sampatrilat is an effecive and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase. Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). |
Targets&IC50 | nACE:171.9 nM(ki), CACE:(ki)13.8 nM |
In vivo | Sampatrilat (p.o.; 30 mg/kg; once a day; 5 weeks) decreases the mortality of the rats with CAL (20% versus 57% for untreated rats) and increase in the survival rate and improvement of the hemodynamic function of the rats with CAL [2]. |
Synonyms | UK-81252 |
Molecular Weight | 584.68 |
Formula | C26H40N4O9S |
CAS No. | 129981-36-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sampatrilat 129981-36-8 Others UK-81252 UK81252 UK 81252 inhibitor inhibit